Skip to main content

View full-text article in PMC

. 2010 Nov 9;5(11):e13916. doi: 10.1371/journal.pone.0013916

Table 1. Summary of vaccine regimens.

Trial	Prime Immunizations			Boost Immunizations			HIV-1 strains	Adjuvant
	Type	Dose	Weeks	Type	Dose (µg)	Weeks
HVTN 041	N/A	N/A	N/A	gp120 protein	5, 20, or 100	0, 4, 12	W61D	AS02_A ^#
HVTN 203	Canarypox	10^7.26 TCID50	0, 4, 12, 24	gp120 protein	600	12, 24	MN, GNE8	Alum
DP6-001	DNA	1.2 mg	0, 4, 12	gp120 protein	375	20, 28	A, B, Bal, C, E^*	QS21

# QS-21 & 3D-MPL in o/w emulsion.

*A: 92UG037 B: 92US715 Bal: Ba-L C:96ZM651 E: 93TH976.